Author details

Full Name

Harry Kleanthous

Affiliation

ORCID

Career Start Year

1988

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37163615	Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.	Sci Transl Med	2023
37932241	Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).		2023
37620306	Antibody-mediated NK cell activation as a correlate of immunity against influenza infection.		2023
36967286	Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWEâ¿¢.		2023
36711543	Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2.	bioRxiv	2023
37376419	Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018 Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen.		2023
36610932	Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.		2023
36921600	Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination.	Cell Rep Med	2023
35100294	Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells.	PLoS ONE	2022
35606518	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.	NPJ Vaccines	2022
35666264	Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.	Human Vaccines and Immunotherapeutics	2022
35976993	Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.	Sci Transl Med	2022
35469152	Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of toxin B.	Current Research in Structural Biology	2022
35294244	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.	Science advances	2022
34711846	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.	npj Vaccines	2021
33688647	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.	bioRxiv	2021
34282417	A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates.		2021
34196304	Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.	J Clin Invest	2021
33873199	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.	Nature	2021
33594366	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.	bioRxiv	2021
34619077	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.	Cell	2021
34493582	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice.	Proc Natl Acad Sci U S A	2021
31811019	A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.	J Immunol	2020
31826999	Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.	J Virol	2020
31718902	Proteomic profiling of precipitated Clostridioides difficile toxin A and B antibodies.	Vaccine	2020
31383487	Corrigendum to "A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains" [Vaccine 37 (2019) 2369-2376].	Vaccine	2019
31641082	FcÎ³ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.	mBio	2019
31882800	Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.	Sci Rep	2019
30429350	Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.	J Virol	2019
31291153	Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.	Hum Vaccin Immunother	2019
31493950	Comparison of adjuvants to optimize influenza neutralizing antibody responses.	Vaccine	2019
31122858	Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.	Vaccine	2019
30905528	A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.	Vaccine	2019
29167342	Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.	J Virol	2018
30510776	Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.	npj Vaccines	2018
29920563	Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine.	PLoS ONE	2018
30185594	Development of a Pan-H1 Influenza Vaccine.	J Virol	2018
30181550	Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.	Scientific Reports	2018
28315708	2016 International meeting of the Global Virus Network.	Antiviral Research	2017
28899628	A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector.	Vaccine	2017
28978710	Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.	J Virol	2017
28978709	Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.	J Virol	2017
28925795	Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets.	Human Vaccines and Immunotherapeutics	2017
29046433	A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.	Science Translational Medicine	2017
28778613	Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.	Vaccine	2017
29091724	Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.	PLoS One	2017
29805776	Clinical and microbiological parameters of naturally occurring periodontitis in the non-human primate <i>Macaca mulatta</i>.	J Oral Microbiol	2017
26857577	Limitations of Murine Models for Assessment of Antibody-Mediated Therapies or Vaccine Candidates against Staphylococcus epidermidis Bloodstream Infection.	Infection and Immunity	2016
29263860	A therapeutic gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis.	npj Vaccines	2016
27238375	Core bead chromatography for preparation of highly pure, infectious respiratory syncytial virus in the negative purification mode.	Vaccine	2016